An Open-Label, Phase I/II Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
Purpose:
Phase I: Determine the optimal dose and schedule of GO and zosuquidar when used in
combination.
Phase II: Determine the complete remission rate (CR+CRp)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
KAN-979-02
NCT00233909
October 2005
March 2008
Name | Location |
---|